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Abstract: 
Aims/hypothesis: Sphingolipid synthesis is typically initiated by the conjugation of L-serine 
and palmitoyl-CoA, a reaction catalyzed by the serine-palmitoyltransferase (SPT). SPT can 
also metabolize other acyl-CoAs (C12 to C18) and other amino acids such as L-alanine and 
glycine giving rise to a spectrum of atypical sphingolipids. Here, we aimed to identify 
changes in plasma levels of these atypical sphingolipids to explore their potential as 
biomarkers in the metabolic syndrome and diabetes. 
Methods: We compared the plasma profile of ten sphingoid bases in healthy individuals to 
patients with the metabolic syndrome but no diabetes and diabetic patients (n=25 per 
group). The results were verified in an STZ rat model. Univariate and multivariate statistical 
analysis was used.  
Results: Deoxysphingolipids (dSLs) were significantly elevated (p= 5E-6) in patients with  the 
metabolic syndrome (0.11 µmole/l ±0.04)   compared to controls (0.06 µmole/l ±0.02) but 
did not differ between the metabolic syndrome and diabetes groups whereas C16-
sphingosine based sphingolipids were significantly lowered in diabetic patients but not in  
patients with the metabolic syndrome without diabetes (p=0.008). Significantly elevated dSL 
levels were also found in plasma and liver of the STZ rats.  A principal component analysis 
revealed a similar or even closer association of deoxysphingolipids with diabetes and the 
metabolic syndrome in comparison to the established biomarkers. 
Conclusions/interpretation: We showed that deoxysphingolipids are significantly elevated in 
patients with type 2 diabetes mellitus and non-diabetic metabolic syndrome compared to 
healthy controls. They might, therefore, be useful novel biomarkers to improve risk 
prediction and therapy monitoring in these patients. 
 
Keywords: deoxysphingolipids, atypical sphingolipids, metabolic syndrome, type 2 diabetes 
mellitus, biomarker 
Abbreviations: The nomenclature used in this paper generally conforms to the 
recommendations of the IUPAC-IUB Comission of Biochemical Nomenclature [1] C16SO or C16 
D-erythro-sphingosine, (2S,3R,4E)-2-amino-4-hexadecen-1,3-diol; C16SA or C16-D-erythro-
sphinganine, (2S,3R,4E)-2-aminohexadecan-1,3-diol; C17SO, (2S,3R,4E)-2-amino-4-
heptadecen-1,3-diol; C17SA, (2S,3R,4E)-2-aminoheptadecan-1,3-diol; C18SO , (2S,3R,4E)-2-
amino-4-octadecen-1,3-diol; C18SA, (2S,3R,4E)-2-aminooctadecan-1,3-diol; C20SO, (2S,3R,4E)-
2-amino-4-icosen-1,3-diol; C20SA, (2S,3R,4E)-2-aminoicosan-1,3-diol, SPT, serine-
palmitoyltransferase, dSL, deoxysphingolipids 
 
 
Introduction: 
The pathogenesis of diabetes mellitus type 2 is characterized by the development of insulin 
resistance, frequently because of excess body fat, that is initially overcome by increased 
insulin secretion and – after several years - a subsequent decrease in the functional 
pancreatic β-cell mass that can no longer compensate for insulin resistance [2-4]. Insulin 
resistance or the compensating hyperinsulinemia lead to the manifestation of a cluster of 
risk factors like hyperglycemia, hypertrigylceridemia, low plasma levels of high density 
lipoprotein (HDL) cholesterol and arterial hypertension which has been termed the 
metabolic syndrome. Although much progress [5] has been made in the understanding of 
the mutual relationships between obesity, insulin resistance, type 2 diabetes and 
atherosclerosis, the complete picture remains elusive. In the last years the carbohydrate 
centered view of the pathogenesis of diabetes has widened to include different classes of 
lipids [5-7] and inflammatory factors [8]. Mounting evidence suggests that sphingolipids play 
a role in the pathogenesis of insulin resistance and diabetes [9-11]. In particular, ceramides 
have been suggested to be important in the development of insulin resistance. For instance, 
inhibition of ceramide synthesis restored insulin sensitivity in palmitate-induced insulin 
resistance in mice [12]. 
Sphingolipids comprise a heterogeneous class of lipids that are derived from the aliphatic 
amino-alcohol sphingosine, which is commonly formed from the precursors L-serine and 
palmitoyl-CoA (suppl. Fig. 1). This reaction is catalyzed by the enzyme serine 
palmitoyltransferase (SPT). Besides these substrates, SPT metabolizes also other acyl-CoAs 
with a carbon chain length in the range of C12 to C18 [13]. Moreover, SPT shows also flexibility 
towards the use of other amino acid substrates such as L-alanine or glycine [14, 15] which 
generates an atypical category of 1-deoxy-sphingoid bases. Whereas the conjugation of 
alanine forms deoxy-sphinganine (doxSA), the use of glycine results in the formation of 
deoxymethyl-sphinganine (doxmethSA). These two metabolites can be N-acylated to form 
deoxysphingolipids (dSL) but not further metabolized to complex sphingolipids due to the 
missing C1-hydroxyl group [16]. Consequently, those metabolites cannot be degraded by the 
canonical sphingolipid degradation pathway which requires the formation of sphingosine-1-
phosphate (S1P) as a catabolic intermediate. Low dSL levels are ubiquitously found in human 
plasma but levels are greatly increased in HSAN1 (OMIM162400), an inherited sensory 
neuropathy which is caused by missense mutations in SPT [15]. 
Physiologically, de-novo sphingolipid synthesis represents a metabolic cross point which 
interconnects lipid, amino acid and thereby indirectly also carbohydrate metabolism. 
Fluctuations in fatty acid and thereby acyl-CoA concentration are reflected in an altered 
carbon chain compositions of the sphingoid bases [12, 17]. Another node connects serine 
and alanine metabolism to the sphingolipid metabolism. Serine is formed from 3-
phosphogylcerate whereas alanine can be converted from and to pyruvate through alanine 
aminotransferase (ALT) in a reversible transaminase reaction. The precursors for both amino 
acids are hence generated during glycolysis and thereby provide a functional link between 
sphingolipid and carbohydrate metabolism. In this respect, it is noteworthy that alanine is 
the major gluconeogenic amino acid with an important role in obesity and diabetes [18, 19]. 
In the light of these metabolic connections and the increasing evidence that certain 
sphingolipid molecules play a role in the pathogenesis of insulin resistance and diabetes, we 
compared the plasma sphingoid base profile of healthy humans to patients with the 
metabolic syndrome but no diabetes and patients with type 2 diabetes mellitus. The 
observed differences were further confirmed in a diabetic animal model.  
 
 
2. Methods: 
2.1 Patients:  
A sex- and age-matched nested cohort of 25 patients with non-diabetic  metabolic 
syndrome, 25 patients with metabolic syndrome and  type 2 diabetes mellitus, and 25 
controls without diabetes and  metabolic syndrome was selected from a previously 
described study cohort [20] of the VIVIT institute (Feldkirch, Austria). The samples were 
derived from a larger cohort of unselected Caucasian patients undergoing coronary 
angiography for the evaluation of suspected coronary artery disease.  Only patients with 
negative angiographic results were enrolled in this study. Age range was 55 - 69 years. The 
angiographers were not aware of plasma sphingolipid levels. The study was approved by the 
Ethics Committee of the University of Innsbruck and all participants gave written informed 
consent. 
According to NCEP-ATPIII criteria, non-diabetic metabolic syndrome was diagnosed if three 
or more of the following criteria were fulfilled: waist circumference >102 cm in men and >88 
cm in women, triglycerides ≥ 1.7 mmol/l (150 mg/dl), HDL cholesterol < 1.0 mmol/l (40 
mg/dl) in men and <1.3 mmol/l (50 mg/dl) in women, blood pressure ≥130 / ≥85 mmHg, and 
fasting glucose ≥6.1 mmol/l (110 mg/dl) but <7 mmol/L. Type 2 diabetes mellitus was 
diagnosed by either fasting glucose levels ≥ 7 mmol/l (126 mg/dl), or plasma glucose levels ≥ 
11.1mmol/l (200 mg/dl) 2h after an oral challenge with 75g glucose or previously diagnosed 
diabetes. Controls were defined by the absence of both non-diabetic metabolic syndrome 
and type 2 diabetes mellitus 
 
2.2 Clinical Chemistry 
Venous blood samples were collected after an overnight fast of at least 12 hours before 
angiography was performed, and laboratory measurements were performed from fresh 
serum samples. The serum levels of triglycerides, total cholesterol, and high density 
lipoprotein (HDL) cholesterol were determined by using enzymatic hydrolysis and 
precipitation techniques (Triglycerides GPO-PAP, CHOD/PAP, QuantolipLDL, QuantolipHDL; 
Roche, Basel, Switzerland) on a Hitachi-Analyzer 717 or 911. Glycated hemoglobin (HbA1c) 
was determined by high-performance liquid chromatography on a Menarini-Arkray KDK HA 
8140 (Arkray KDK, Kyoto, Japan). Clinical chemistry parameters were measured on a Hitachi 
717 or 911 system (Roche, Basel, Switzerland). 
 
2.3 Animal model 
 
Male Sprague Dawley rats (180-200 g, Charles River, Calco, Italy) were housed in groups of 
two rats. Animal room temperature and relative humidity were set at 22±2°C and 55±10%. 
Artificial lighting provided a 12 hours light/12 hours dark cycle (7 a.m. – 7 p.m.). The animals 
had free access to diet and water. Diabetes was induced in rats fasted overnight by a single 
intraperitoneal (i.p.) injection of 60 mg/kg of STZ dissolved in sodium citrate buffer (pH 4.5). 
The control rats were injected with vehicle. Hyperglycemia was confirmed by measuring 
glycosuria 72 h after STZ injection, using Keto-Diabur test 5000 strips (Roche Diagnostics Spa, 
Italy). Only animals with glycosuria > 5% were classified as diabetic and included in the study. 
Body weight and blood glucose concentration, determined by tail bleeding using strips 
(Ascensia Elite; Bayer, Basel, Switzerland), were measured weekly. Immediately after 
sacrificing the animals, liver and muscle (Gastrocnemius) were carefully dissected out and 
immediately frozen in liquid N2. 
 
2.4 Quantification of sphingoid bases  
The lipids were analyzed as described before [15, 21]. Tissue samples were homogenized in 
lysis buffer (25mM Hepes pH8, 0.2% TX100) using Precellys® 24 tissue homogenizer (Bertin 
technologies, Montigny-le-Bretonneux, France). Briefly, 100µl plasma or tissue homogentate 
containing 80 µg extracted protein were added to 1ml of extraction buffer (2:1) methanol-
KOH/chloroform and spiked with 200 pmoles of the internal standard C20 sphinganine 
(Avanti Polar Lipids).   
The extracted dried lipids were acid hydrolyzed using methanolic HCl (1N HCl/10M water in 
methanol) and heat (65 oC, 16 h) to release the sphingoid base backbones which was 
followed by a second extraction. LC/MS analysis was performed as described earlier [15]. 
Lipids were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, Interchim, 
France) and analyzed by an MS detector (LCQ, Thermo Inc.). The samples were measured as 
singletons for each subject. Inter- and intra-assay CV% was between 5% and 20% for each 
sphingoid base.  
Analyzed sphingoid bases included C16SO, C16SA, C17SO, C17SA, C18SO, C18SA, C20SO, C18SA-
diene, doxSA, and doxSO. 
 
2.5 Statistics: 
Mean comparison and ROC curve analyses  
The original dataset was imported into SPSS 16.0 (SPSS Switzerland AG, Zurich, Switzerland). 
Since some of the measured variables did not follow normal distribution, even after 
transformations, non-parametric tests were used. Kruskal- Wallis test was used to compare 
all three groups. Mann-Whitney U test was used for comparisons between two groups and 
then followed by the Bonferroni correction. Spearman correlations were calculated. Receiver 
Operating Characteristic (ROC) curve analysis was performed and the two-tailed asymptotic 
p value was calculated for the ROC areas under the curve. 
 
Orthogonal partial least square- discriminant analysis (OPLS-DA)  
OPLS-DA [22, 23] was used as a multivariate predictive and regression method which is 
based on the concepts of principal component analysis (PCA). In PCA, a large number of 
correlated variables e.g. clinical, clinical chemistry and sphingolipid variables are summarized 
into a smaller number of uncorrelated ones called principal components. Thus, the 
correlation structures are preserved while reducing the number of variables. In contrast to 
PCA, which does not consider class membership, in OPLS-DA the group information is 
included (control, the non-diabetic metabolic syndrome and diabetes) as a Y variable. OPLS-
DA, therefore, summarizes the data into a predictive component maximizing the between-
group variation and an orthogonal component(s) describing the within-group variation. The 
predictive component describes the variations in X which correlate with Y. The orthogonal 
component describes the systematic variations within each group which do not correlate 
with Y, thereby removing the noise data from the predictive component. 
For any modeling technique, model evaluation is necessary before any inferences are made. 
R2Y reports the fit of the model to the original dataset and Q2Y reports the predictive ability 
of the model calculated by cross validation. Cross validation (CV) is performed by dividing 
the whole dataset into multiple random groups and then predicting the class assignment of 
members of each group at a time. 
The dataset was imported into SIMCA-P+ ®12.0.1.0 (Umetrics Inc., Umeå, Sweden) for the 
calculations.  The groups (control, non-diabetic metabolic syndrome and diabetes) were 
assigned as classes. Variables which did not follow the normal distribution were log 
transformed before model fitting. Since some variables did not follow the normal 
distribution after log transformation, models were fitted twice, once with the log-
transformed variables and another time without any transformations. The model evaluation 
parameters and interpretations did not differ in both cases. Therefore, the values for all the 
variables without any transformations were used. As the values for the variables had 
different scales, the dataset was normalized in unit variance (UV) and centered around the 
mean. OPLS-DA models were fitted for the classes to get the highest R2Y and Q2Y values. 
Models were done to compare 2 groups only at a time (control vs. non-diabetic metabolic 
syndrome and non-diabetic metabolic syndrome vs. diabetes). We refrained from the use of 
the three groups as a Y variable since it made the interpretations of the model results more 
complex.  
Since PCA-based methods are sensitive to outliers, Hotelling`s T2 and distance to the model, 
DmodX, were utilized to detect outliers. Hotelling`s T2 is a generalization of the t distribution 
for the multivariate case and is usually visualized in score plots. Score plots show on the x 
axis the scores of the predictive component describing the between-group variation and on 
the y axis the scores of the orthogonal component describing the within-group variation. 
Tolerance ellipse is drawn in score plots outlining the 95% probability of the Hotelling’s T2 
distribution. Scores for observations situated outside the tolerance ellipse can be considered 
as outliers. Moreover, DModX shows the distance to the model in the X space in a way 
similar to the residuals in the linear regression models. A critical value D-Crit of 0.05 was set 
as a limit for outlier detection. After outliers were detected, models were fitted twice, 
excluding and including the outliers. In the current study, no difference was found in the 
model evaluation parameters or any of the results upon inclusion or exclusion of the 
outliers. Therefore, models without outlier removal were used for the interpretation.  
 Cross validation (CV) was performed for each model with 7 groups. The CV-ANOVA was 
calculated along with misclassification tables and Fisher`s probabilities  
 
Results: 
For this study, we analyzed plasma samples of patients from three pre-defined subgroups 
each consisting of 25 sex- and age-matched patients with either manifest diabetes mellitus 
type 2, metabolic syndrome but no manifest diabetes mellitus, or without diabetes mellitus 
or metabolic syndrome (controls). Results are summarized in Table 1.  
Sphingoid bases in plasma are usually N-aceylated but also conjugated with different 
headgroups giving rise to a great variety of different sphingolipid species. To analyze the 
sphingoid base composition of these metabolites we subjected the extracted lipids a 
sequential acid and base hydrolysis to remove the N-acyl chain and head group. The 
resulting free sphingoid bases were analyzed by LC-MS. 
The most abundant sphingoid base in human plasma was C18-Sphingosine (C18SO) followed 
by C18SA-diene, C16-Sphingosine (C16SO) and C17-Sphingosine (C17SO).  Deoxy-sphingolipids 
were generally recovered as quantitatively minor fractions representing 0.1-0.3% of the total 
sphingoid bases 
Plasma concentrations of total deoxy-sphingolipids (dSL) were significantly higher for the 
non-diabetic metabolic syndrome group (0.11 µmol/l ±0.04) compared to controls (0.06 
µmol/l ±0.02) but did not differ between the metabolic syndrome and diabetic groups (Table 
1). This elevation remained significant after the Bonferroni correction for multiple testing. In 
contrast, C16SO levels were found to be significantly lower (p= 0.008) in diabetic patients 
(6.37 µmol/l ± 2.82) in comparison the non-diabetic metabolic syndrome (8.38 µmol/l ± 
2.25) patients. However, this decrease missed the significance limit after Bonferroni 
correction in which a significance level of 0.05 corresponds to a p value of 0.002. Other 
sphingoid bases were not significantly different between the three groups.  
A correlation matrix of all variables (clinical data, clinical chemistry measurements along 
with sphingoid base backbone measurements) showed a significant correlation of the serine-
based sphingolipids (C16, C17 or C18 SA or SO and C18 SA-diene) with LDL and total cholesterol 
but less with HDL cholesterol. In contrast, the alanine based dSLs showed a strong 
correlation to the  metabolic syndrome related variables like waist circumference (wcf) and 
triglycerides (suppl. Figure 2). Therefore, we were interested to see whether the increased 
dSL levels are associated with hyperglycemia per se or rather with insulin resistance. To 
address this issue we analyzed plasma, liver and muscle tissue of streptozotocin (STZ) 
treated rats (Table 2). Although beta cell failure and not insulin resistance is at the base of 
the STZ rat model we also found significantly elevated dSL levels in plasma and liver of the 
STZ rats (Table 2, Fig. 1). No dSL’s were detected in muscle tissue. This suggests that plasma 
dSLs are primarily elevated in association with hyperglycemia and probably of hepatic origin. 
An orthogonal partial least square-discriminant analysis (OPLS-DA) was used to estimate the 
importance of the individual variables as discriminating biomarkers. Both models (control vs.  
non-diabetic metabolic syndrome and  non-diabetic metabolic syndrome vs. diabetes) 
showed good fit and predictive power. Therefore, they are valid for discrimination. (suppl. 
Table 1). 
In score plots (Fig. 2a) clustering into separate groups is still preserved after reducing the 
whole dataset into a single predictive component (shown on the x axis) and an orthogonal 
one (shown on the y axis). Loading plots (Fig. 2b) show the weights of each of the original 
variables to the model and hence its contribution to the disease state.  In the control vs. the 
metabolic syndrome loading plot, triglycerides, doxSA ,doxSO, diastolic and systolic blood 
pressure contributed  to the  metabolic syndrome state model (95% confidence interval >0) 
whereas elevated HDL cholesterol contributed to the control state model (95%confidence 
interval <0). This confirms the biological and clinical validity of the model since elevated 
triglycerides, low HDL cholesterol as well as hypertension are key features of the metabolic 
syndrome. DoxSA and doxSO were identified as the second and fourth most important 
contributors to the metabolic syndrome model just next to triglycerides and HDL cholesterol 
respectively, but above glucose, waist circumference and systolic blood pressure (Fig. 2b and 
c). In the  metabolic syndrome vs. diabetes model, we found elevated fasting glucose and 
glycated haemoglobin (HbA1c) concentrations together with low C16SO and creatinine levels 
to be the  contributors for the diabetes state model (Fig. 2b). 
Variable importance for the projection (VIP) plots (Fig. 2c) show the contribution of each 
variable to the variation in both the X space and the Y space (hence its correlation with other 
variables and the control or disease state). A coefficient value >1 signifies that the variable is 
important.  For the control vs. metabolic syndrome model, the VIP plot showed for 
triglycerides, doxSA, HDL cholesterol, and doxSO the highest VIP coefficients. A slight 
importance (VIP coefficient slightly >1) was noticed for diastolic pressure and fasting glucose. 
For the  metabolic syndrome vs. type 2 diabetes mellitus model a significant importance of 
HbA1c, glucose and C16SO was seen. VIP coefficients were also >1 for body mass index, HDL 
cholesterol and creatinine. 
In summary, the OPLS-DA analysis revealed that triglycerides, doxSA, doxSO and HDL 
cholesterol are the best explanatory variables for the non-diabetic metabolic syndrome 
while differences in HbA1c, glucose and C16SO were mostly related to the diabetes. 
The diagnostic potential of these markers was analyzed in a Receiver Operating 
Characteristic (ROC) curve analysis (Fig. 3). For the diagnosis of the metabolic syndrome, 
doxSA and doxSO had an area under the curve (AUC) of 0.875 and 0.842 respectively 
(p<0.001). Moreover, C16SO showed an AUC of 0.282 (corresponding to 0.718; p<0.01). 
 
Discussion: 
In this study, we compared the plasma sphingoid base composition of healthy individuals 
with non-diabetic metabolic syndrome and diabetic patients. We found that deoxy-
sphingolipids (dSL) are significantly elevated in the plasma of patients with either non-
diabetic  metabolic syndrome or type 2 diabetes mellitus compared to controls but not 
different between non-diabetic  metabolic syndrome and diabetic patients. In contrast, 
C16SO levels were lower in diabetic patients but did not differ between controls and 
metabolic syndrome patients. Other sphingoid base metabolites were not different between 
the groups (Table 1).  
This indicates that the metabolic changes in the metabolic syndrome and type 2 diabetes 
mellitus are specifically associated with alterations in some but not all sphingoid base 
species. Elevated dSL levels were also confirmed in plasma and liver tissue of a type 1 
diabetes model (STZ rats) indicating that the observed increase in dSLs is independent of the 
type of diabetes. 
Sphingolipid metabolism can be considered as a metabolic cross point which interconnects 
fatty acid (acyl-CoA) and amino acid (serine and alanine) metabolism. Serine and alanine 
formation is thereby linked to glycolysis which forms their precursors 3-phosphoglycerate 
and pyruvate respectively. 
The metabolic syndrome and type 2 diabetes mellitus are associated with the clustering of 
several risk factors. To delineate the relative contribution of each variable we used a 
supervised learning approach (OPLS-DA) [24, 25]. This analysis showed that dSL levels have, 
in addition to triglycerides and HDL cholesterol, the highest explanatory power for the 
metabolic syndrome. In this context it has to be considered that the metabolic syndrome 
and type 2 diabetes mellitus are clinically not two completely separated entities. Most 
diabetic patients also fulfill the criteria for the metabolic syndrome which, by itself, is 
associated with insulin resistance. In fact, most diabetic patients have presented for many 
years with the metabolic syndrome before hyperglycemia manifests. The observation that 
dSL levels are not different between non-diabetic metabolic syndrome patients and diabetic 
patients suggests that the dSLs are already formed in the pre-diabetic situation when insulin 
insensitivity is still compensated by increased insulin production and hyperinsulinemia. 
In contrast, C16SO together with glucose and HbA1c were the strongest contributors for the 
diabetes model. C16SO is generated by the use of myristoyl-CoA instead of palmitoyl CoA - a 
reaction which is primarily catalyzed by the SPTLC3 subunit of SPT [13]. 
It should be noted at this point that we also found significant levels of C17SO in the analyzed 
plasma samples. C17SO is considered to be an “unnatural” sphingoid base and therefore 
sometimes used as an internal normalization standard in lipidomics. However, the identity of 
C17SO in human plasma was validated by comparison to a commercial, synthetic C17SO 
standard and also reported earlier by Quehenberger et al. [26]. This indicates that the use of 
C17SO as an internal standard in particular for plasma samples has to be taken with 
precaution.  
Currently we do not fully understand why plasma dSL levels are increased in the metabolic 
syndrome and diabetes. Deoxysphingolipids are almost exclusively present in VLDL and LDL 
but not in HDL indicating that the dSLs in plasma are primarily of hepatic origin [27]. This 
view is supported by the observation that dSL levels were elevated in liver and plasma of STZ 
rats but not present in skeletal muscle. A possible explanation for the increased dSL 
formation might be an increase hepatic availability of alanine. Recent reports show that 
lifestyle modifications in the metabolic syndrome are associated with significant changes in 
the plasma amino acid profiles [28]. In obese individuals increases of both, skeletal muscle 
output of alanine and hepatic uptake of alanine were seen while serine levels were not 
changed [18]. Furthermore hepatic glucose uptake is primarily mediated by GLUT2 and 
hence insulin independent. Hyperglycemic conditions are therefore associated with elevated 
hepatic glucose levels and an increased glycolytic flux which increases the formation of 
pyruvate and its anaerobic conversion into either lactate or alanine. Elevated glucose levels 
could hence increase hepatic alanine levels and thereby dSL generation. This model implies 
that dSL levels are elevated independent of the type of diabetes which is supported by the 
observation that dSL levels were also found to be elevated in plasma and liver of a type 1 
diabetes animal model (STZ rats). In both conditions even short-term and transient 
fluctuations in plasma glucose levels might be integrated in an increased dSLs formation 
which by themselves might have a slow turnover since they are not degraded by the 
canonical sphingolipid catabolism. 
Another interesting aspect is whether increased plasma dSL levels as well as decreased 
plasma C16SO levels contribute to the pathogenesis of diabetes and its complications. 
Genome-wide association studies showed a strong association of genetic SPTLC3 variants 
with alterations in lipid metabolism [29] and increased risk for myocardial infarction [30].  
Therefore lower C16SO levels might be directly or indirectly related to the increased risk of 
diabetic patients for developing cardiovascular complications. 
Previously, we showed that the increased formation of dSLs is the pathological cause for the 
inherited neuropathy HSAN1 [15, 31]. Clinically, HSAN1 closely resembles the diabetic 
peripheral neuropathy (DPN) which occurs in about 60% of diabetic patients. Both 
conditions show a late onset, slow progression and length dependent axonopathy. All 
peripheral nerves are affected, including pain fibers, motor neurons and autonomic nerves. 
The degeneration of small sensory fibers results in the loss of pain sensation, which in turn 
leads to painless injuries. Furthermore, HSAN1 and DPN are both associated with skin ulcers, 
which is not a common feature in other peripheral neuropathies. Considering the neurotoxic 
properties of dSLs, it might therefore be conceivable that the increased dSLs formation is not 
only interesting from the aspect as biomarkers but also as potential pathogenic agents in the 
diabetic peripheral neuropathy (DPN). Interstingly, it has been shown recently that serum 
triglycerides correlate with the progression of the diabetic neuropathy [32]. In parallel we 
observed a strong correlation of the dSLs and triglyceride levels (suppl. Figure 2). 
Taken together our results suggest that dSLs are relevant biomarkers for both the metabolic 
syndrome and type 2 diabetes mellitus whereas C16SO bases seem to specifically lowered in 
diabetes, possibly reflecting the risk for developing cardiovascular complications. Therefore, 
a combination of these markers might help to improve the risk prediction and therapy 
monitoring of diabetic patients. This could be especially relevant in the transition phase of a 
pre-diabetic to diabetic state. A limitation of this study is the rather small group size. 
However, for a pilot biomarker study it is valid to use small numbers as long as type I and 
type II errors are considered carefully. We showed p value in the order of 1e-5 after the 
most conservative correction for doxSA and doxSO which goes very well with rejecting the 
null hypothesis. However, larger and ideally prospective follow-up studies are needed to 
further validate the potential of these metabolites and to explore their diagnostic and 
prognostic value. Finally, a more detailed knowledge of the physiological and 
pathophysiological properties of these metabolites is important to better understand the 
interplay between sphingolipids, carbohydrate metabolism, insulin resistance and diabetes. 
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  Control 
(n=25) 
Metabolic 
Syndrome (n=25) 
Diabetes  
(n=25) 
KruskalWallis 
p-value 
Mann-Whitney U p-value 
 Mean±SD Mean±SD Mean±SD  C vs MetS MetS vs D 
AGE 61.19±4.28 62.13±5.02 61.56±4.64 0.771 
 
0.50 0.567 
Female (%) 40 40 40 1.000   
Smoking (%) 64 56 60 0.846   
Wcf (cm) 98.24±12.10 105.84±8.23 110.80±11.97 3.70E-04 0.004 0.051 
BMI 28.19±4.49 30.13±3.01 32.21±4.83 0.006 0.05 0.09 
Fast. Gluc. (mmol/l) 5.26±0.56 5.64±0.57 9.59±4.16 1.94E-09 0.03 4.29E-07 
HbA1c (%) 5.60±0.33 5.76±0.34 7.79±2.04 4.71E-10 0.17 9.52E-08 
Chol(mmol/l) 5.26±1.24 4.99±1.30 4.98±1.44 0.777 0.49 0.861 
LDL(mmol/l) 3.35±0.96 3.45±1.00 3.16±1.22 0.449 0.52 0.269 
HDL(mmol/l) 1.80±0.69 1.15±0.21 1.31±0.32 1.60E-05 2.37E-06 0.132 
TG(mmol/l) 1.10±0.37 2.51±0.83 2.21±1.47 1.96E-07 1.38E-08 0.067 
sysBP (mmHg) 126.80±12.47 133.84±15.23 135.52±15.92 0.081 0.12 0.44 
diasBP (mmHg) 78.80±8.50 83.92±9.41 82.24±8.99 0.161 0.06 0.565 
AST 28.56±8.60 30.84±24.10 25.84±8.43 0.388 0.38 0.662 
ALT 29.92±15.71 34.76±24.54 31.68±13.25 0.650 0.35 0.907 
Crea 0.84±0.18 0.92±0.21 0.81±0.23 0.144 0.20 0.06 
GFR 100.65±11.53 95.26±15.30 100.77±15.68 0.316 0.22 0.184 
C16SO (µmol/l) 8.31±4.49 8.38±2.25 6.37±2.82 0.041 0.55 0.008 
C16SA (µmol/l) 0.23±0.13 0.23±0.10 0.26±0.14 0.749 0.84 0.491 
C17SO (µmol/l) 4.66±2.42 4.02±1.10 3.71±1.48 0.387 0.64 0.29 
C17SA (µmol/l) 0.15±0.07 0.14±0.05 0.14±0.05 0.960 0.82 0.961 
SO (µmol/l) 88.83±27.23 81.66±21.28 81.54±23.89 0.622 0.34 0.793 
SA (µmol/l) 2.17±0.9 2.20±0.77 2.57±1.14 0.473 0.82 0.299 
C20SO (µmol/l) 0.20±0.08 0.19±0.06 0.19±0.05 0.727 0.46 0.839 
doxSO (µmol/l) 0.15±0.09 0.23±0.09 0.24±0.13 2.14E-04 3E-05 0.839 
doxSA (µmol/l) 0.06±0.02 0.11±0.04 0.12±0.05 3.92E-06 5E-06 0.808 
C18SA-dienine 
(µmol/l) 
20.79±8.17 18.27±5.74 16.42±6.80 0.148 0.36 0.273 
 
Table 1. Baseline characteristics and results. Values are expressed as means or percentage 
for scale or categorical variables respectively. P-values were calculated with Kruskal-Wallis 
test for all three group - and with Mann-Whitney-U for two group comparisons. After 
Bonferroni correction a p value of 0.002 corresponded to a significance level of 0.05. For the 
categorical variables asymptotic two sided p-values for the Chi-square are shown. (C for 
controls, MetS for the metabolic syndrome group and D for the diabetic patients group) 
  Liver (pmol/100 µg prot) Muscle (pmol/100 µg prot) Plasma (µmol/l) 
 CTRL STZ CTRL STZ CTRL STZ 
Glucose 
(mmol/l) - - - - 
8.8 ± 0.4 53.8 ± 3.3** 
C16SO  3.4 ± 0.8 3.1 ± 0.7 1.5 ± 0.23 1.4 ± 0.24 0.06 ± 0.02 0.09± 0.07 
C17SO  15.7 ± 3.3 13 ± 2.5 4.2 ± 0.44 5.0 ± 1.2 0.3 ± 0.1 0.4 ± 0.1 
C18SA-dienine  64.1 ± 10.6 78.1 ± 26.1 11.2 ± 2.3 21.5 ± 10.3* 2.6 ± 0.4 5.0 ± 0.9* 
SO  1130 ± 189 1127 ± 252 180 ± 25.4 262 ± 106* 24.3 ± 7.6 29.1 ± 4.8 
SA  40.3 ± 9.4 66.4 ± 29* 9.1 ± 1.8 8.1 ± 2.6 1.0 ± 0.5 1.6 ± 0.6* 
C20SO  10.8 ± 4.4 11.4 ± 2 6.5 ± 0.6 6.7 ± 1.6 0.1 ± 0.08 0.15 ± 0.9 
doxSA 0.2 ± 0.08 0.4 ± 0.12** n.d n.d 0.01 ± 0.003 0.12 ± 0.9** 
doxSO  n.d n.d n.d n.d n.d n.d 
 
Table 2. Results of STZ rat tissue and plasma analysis. 
Values are shown as mean±SD, n.d. = non detected, P-values were calculated with Mann-
Whitney-U test (* p-value <0.05, ** p-value < 0.001)  
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Figure 1 Deoxysphinganine (doxSA) levels are significantly (p<0.001) elevated in liver tissue 
(left) and plasma (right) of STZ rats (STZ) compared to controls (Ctr).  
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Figure 2 a) Score plots of OPLS-DA models Control (Contr) vs. non-diabetic metabolic 
syndrome (MetS) (left) and non-diabetic metabolic syndrome (MetS) vs. type 2 diabetes 
(T2DM) (right). Individual observations are shown as black triangles for controls, open 
triangles for the metabolic syndrome and black rhombus for type 2 diabetes. On the x axis, 
the scores for each subject in the predictive principal component (t(1)) is shown, while the y 
axis shows the scores for each subject in the orthogonal component. Thus, variations on the 
x axis reflect the between-group separation while variations on the y axis show the within-
group variations (noise).   The tolerance ellipse corresponds to 95% of the Hotelling`s T2 
multivariate distribution. b) Loading column plots of OPLS-DA models control vs. metabolic 
syndrome (left) and metabolic syndrome vs. diabetes (right). The weights represent the 
contribution of each variable to the model component scores. Variables with larger weights 
contribute more to the model. Error bars represent 95% confidence intervals for calculated 
weights. c) Variable importance to the projection (VIP) plot for OPLS-DA models control vs. 
metabolic syndrome (left) and metabolic syndrome vs. diabetes (right). The VIP coefficients 
plot shows the summation of all the weights for each X variable to predict Y and hence 
denoting the importance of each X variable.  
 Figure 3 Receiver Operating Characteristics curves (ROC) a) ROC curves for control vs. 
metabolic syndrome showing triglycerides and HDL cholesterol as predictors of the 
metabolic syndrome with AUC’s of 0.968 (p<0.001) and 0.111 (corresponding to 0.889), 
respectively. The dSLs show comparable AUCs with 0.875 for doxSA and 0.842 for doxSO. b) 
ROC curves for potential biomarkers in metabolic syndrome vs. diabetes. HbA1c and glucose 
are showing an AUC of 0.939 and 0.917 for type 2 diabetes whereas C16SO shows a 
significantly lower AUC of 0.282 (corresponding to 0.718) denoting its decrement in 
association with diabetes. 
